 Smith Nephew PLC shares represent a rare value opportunity, according to a leading investment bank that has reiterated its bullish stance on and price target for stock in the medical devices giant. Credit Suisse reckons November 4s trading update could act as a catalyst for the price, though it admits there may also be some pressures including price and technology pressures and dilutive MA. 